CAPITOL COUNSEL LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 16, 2026

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.